Clinical trials: Opioid-related Disorders
Opioid-induced Bowel Dysfunction
Opioid-induced Bowel Dysfunction (OBD) Pivotal Assessment of Lubiprostone (OPAL)
The primary purpose of the study is to evaluate the efficacy and safety of lubiprostone administration in subjects with Opioid-induced Bowel Dysfunction.
- Trial name
- NCT01298219
- Testing
- Lubiprostone
- Where
- 142 sites in United States, Belgium and 5 more
- Volunteers
- 439 people
- Sponsor
- Sucampo Pharma Americas, LLC
Opiate Dependence, Heroin Dependence
Behavioral Naltrexone Therapy for Promoting Adherence to Oral Naltrexone vs Extended Release Injectable Depot Naltrexone
In pilot study now proposed, we plan to randomly assign 60 opioid dependent patients to the new model, Depot-BNT, or to BNT plus oral naltrexone for a 6-month trial.
- Trial name
- Depot-BNT (NCT00577408)
- Testing
- depot naltrexone, Oral Naltrexone
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- New York State Psychiatric Institute
Opioid-use Disorder, Opiate Dependence
Impact of Lofexidine on Stress, Craving and Opioid Use
Individuals with opioid use disorder who are stabilized on buprenorphine or methadone will be randomly assigned to receive placebo or lofexidine for 5 weeks.
- Trial name
- NCT03718065
- Testing
- Lofexidine
- Where
- United States
- Volunteers
- 112 people
- Sponsor
- Medical University of South Carolina
Opioid-Induced Bowel Dysfunction
Opioid-induced Bowel Dysfunction: Long-Term Assessment of Lubiprostone
The purpose of this study is to evaluate the long-term safety and efficacy of lubiprostone administration in participants with opioid-induced bowel dysfunction.
- Trial name
- NCT00620061
- Testing
- Lubiprostone 24
- Where
- 123 sites in United States, Canada
- Volunteers
- 439 people
- Sponsor
- Sucampo Pharma Americas, LLC
Opioid Dependence
A Study of Adult Outpatients With Opioid Dependence Transitioned From a Daily SL Buprenorphine to Probuphine® Subdermal Implants
The primary objective of the study is to demonstrate maintenance of treatment efficacy when transferring adult outpatients with opioid dependence, who are clinically stabilized on 8 mg or less of sublingual (SL) buprenorphine…
- Trial name
- PRO-814 (NCT02180659)
- Testing
- sublingual buprenorphine tablets, Buprenorphine implant
- Volunteers
- 177 people
- Sponsor
- Titan Pharmaceuticals
Parenting, Opioid-use Disorder
Fathering In Recovery
The majority of men experiencing opioid use disorder and receiving treatment are fathers. Substance use, transitions between in-patient and out-patient treatment, and reunification as a family, all create considerable strain and…
- Conditions
- Parenting, Opioid-use Disorder, Father-Child Relations, Fathers
- Trial name
- FIR (NCT04611542)
- Testing
- Fathering In Recovery
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Oregon Research Behavioral Intervention Strategies, Inc.
Heroin Addiction
Buprenorphine for Prisoners
This five-year study examines the effectiveness of buprenorphine treatment provided to previously-addicted inmates(N=320; 160 males, 160 females) initiated in prison and continued in the community.
- Trial name
- NCT00574067
- Testing
- Buprenorphine +OTP, Buprenorphine +CHC, Counseling +OTP
- Where
- 2 sites in United States
- Volunteers
- 213 people, healthy volunteers welcome
- Sponsor
- Friends Research Institute, Inc.
Opioid Induced Constipation
To Evaluate Patient Preference of Movantik and Polyethylene Glycol 3350 for Opioid Induced Constipation
The purpose of this study is to determine whether patients with opioid induced constipation prefer treatment with naloxegol (Movantik) or with Polyethylene Glycol 3350.
- Trial name
- NCT03060512
- Testing
- Polyethylene Glycol 3350, Movantik
- Where
- 53 sites in United States
- Volunteers
- 276 people
- Sponsor
- AstraZeneca
Opioid-Use Disorder
Biased Opioid Agonists for Treatment of Opioid Withdrawal in OUD
Background: People with opioid-use disorder (OUD) might benefit from having more treatment drugs to choose from. A new drug, TRV734, could be used like methadone to treat OUD. It might not have as many side effects.
- Trial name
- NCT04316559
- Testing
- TRV734, Oxycodone
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- National Institute on Drug Abuse (NIDA)
Buprenorphine, Naloxone
Observational Study of Misuse of High Dose Buprenorphine (Subutex® or Generic) in Opiate-Addicted Patients in France (Study P05186AM1)(COMPLETED)
The purpose of this study is to assess the risks of abuse, misuse and adverse events related to high dose buprenorphine. Approximately 1250 patients taking Subutex (Schering-Plough) or its Buprenorphine High Dose (BHD) generic…
- Conditions
- Buprenorphine, Naloxone, Opiate-related Disorders, Opiate Dependence
- Trial name
- OPUS R (NCT00723697)
- Testing
- buprenorphine
- Volunteers
- 1,307 people
- Sponsor
- Indivior Inc.
Opioid Overdose
Preventing Opioid Overdose Mortality in the United States
This study aims to conduct a randomized controlled trial of 105 syringe services programs (SSPs) throughout the United States to understand the effectiveness of a multifaceted, facilitation-based strategy at advancing naloxone…
- Trial name
- NCT03924505
- Testing
- Organize and Mobilize for Implementation Effectiveness, Dissemination
- Where
- United States
- Volunteers
- 105 people, healthy volunteers welcome
- Sponsor
- RTI International
Brain and Central Nervous System Tumors, Chronic Myeloproliferative Disorders
Methadone, Morphine, or Oxycodone in Treating Pain in Patients With Cancer
RATIONALE: Methadone, morphine, or oxycodone may help relieve pain caused by cancer. It is not yet known whether methadone is more effective than morphine or oxycodone in treating pain in patients with cancer.
- Conditions
- Brain and Central Nervous System Tumors, Chronic Myeloproliferative Disorders, Leukemia, Lymphoma
- Trial name
- NCT00726830
- Testing
- methadone hydrochloride, morphine sulfate, oxycodone hydrochloride
- Where
- 2 sites in United States
- Volunteers
- 1 people
- Sponsor
- M.D. Anderson Cancer Center
Narcotic Abuse
Aprepitant Effects on Oxycodone Response
Addressing the issue of opioid dependence and tolerance has public health implications for the treatment of opioid abuse (both heroin as well as pharmaceutical opioids) and for the treatment of pain.
- Trial name
- NCT00999544
- Testing
- Aprepitant 0mg, Aprepitant 40mg, Aprepitant 200mg
- Where
- United States
- Volunteers
- 9 people, healthy volunteers welcome
- Sponsor
- Sharon Walsh
Opioid Use Disorder
Oxytocin, Stress, Craving, Opioid Use Disorder
Although stress has long been linked to substance use, craving and relapse, there are no available medications that target stress-induced substance use disorder (SUD).
- Trial name
- OSCO (NCT04051619)
- Testing
- intranasal oxytocin, 40 IU, twice a day for 7 days
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Brown University
Hepatitis C, Opioid-Related Disorders
The Kentucky Viral Hepatitis Treatment Study
The overarching goal of the Kentucky Viral Hepatitis Treatment Project (KeY Treat) is to increase hepatitis C virus (HCV) treatment access and delivery in a rural Appalachian community, which is in the midst of the…
- Conditions
- Hepatitis C, Opioid-Related Disorders, Injection Drug Use
- Trial name
- KeY Treat (NCT03949764)
- Testing
- Sofosbuvir/velpatasvir (Epclusa®)
- Where
- United States
- Volunteers
- 380 people
- Sponsor
- Jennifer Havens
Hepatitis C, Opiate Dependence
Effective Treatment of Hepatitis C in Substance Users
We hypothesize that integrating Hepatitis C into methadone and buprenorphine treatment will improve Hepatitis C outcomes as well as drug treatment outcomes in patients who are addicted to opiates.
- Trial name
- NCT00633243
- Testing
- Modified Directly Observed Therapy (mDOT), Self-Administered Therapy (SAT)
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Yale University
Musculoskeletal Pain, Chronic Pain
Living in Full Even With Pain Study
This project will increase our understanding of the mechanisms underlying changes in opioid medication use associated with three psychosocial chronic pain (CP) treatments.
- Trial name
- LIFE (NCT03916276)
- Testing
- Cognitive Therapy (CT), Mindfulness Meditation (MM), Behavioral Activation (BA)
- Where
- United States
- Volunteers
- 91 people
- Sponsor
- University of Washington
Opioid-use Disorder
Project MIMIC (Maximizing Implementation of Motivational Incentives in Clinics)
There is an urgent need for effective treatments for patients with opioid use disorder (OUD). This study will train opioid treatment programs in an evidence-based behavioral treatment called contingency management (CM).
- Trial name
- MIMIC (NCT03931174)
- Testing
- Addiction Technology Transfer Center (ATTC) Training Strategy, Enhanced Addiction Technology Transfer Center (E-ATTC) Training Strategy
- Where
- 29 sites in United States
- Volunteers
- 780 people
- Sponsor
- Brown University
Neonatal Abstinence Syndrome, Neonatal Opiate Withdrawal Syndrome
Buprenorphine Pharmacometric Open Label Research Study of Drug Exposure
Neonatal withdrawal syndrome is a series of signs and symptoms in infants exposed to opioids in utero. Buprenorphine has demonstrated a 40% reduction in length of pharmacologic treatment compared to oral morphine.
- Trial name
- B-PHORE (NCT03608696)
- Testing
- Buprenorphine
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Thomas Jefferson University
Opioid Use Disorder, Chronic Pain
Computer Based Treatment for Cognitive Behavioral Therapy and Cooperative Pain Education and Self-Management
The investigators plan to develop and pilot test an integrated, web-based cognitive behavioral approach and then conduct a randomized clinical trial evaluating its efficacy relative to standard care in a large and diverse sample…
- Trial name
- IMPACT (NCT05204576)
- Testing
- CBT4CBT COPES
- Where
- 3 sites in United States
- Volunteers
- 160 people
- Sponsor
- Yale University